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Edited by Gerrit van MeerAbstract There are numerous examples of how fundamental re-
search has been required to understand and treat human disease.
This article focuses on three human diseases of lipid metabolism
in which advancements in understanding and treatment would not
have been possible without basic research. Fabry disease is an
inherited metabolic disorder caused by the lack of a speciﬁc en-
zyme in glycosphingolipid catabolism. Cardiovascular disease is
a complex and multifactorial disease but as many as half of the
cases can be attributed to abnormal levels of plasma cholesterol.
The incidence of liver disease is increasing due to the current epi-
demic of obesity. It is only recently that curiosity-driven research
has yielded valuable insight into the mechanism by which liver
disease evolves.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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For many of us the title of this article is self-evident. How-
ever, somehow the message often escapes those involved in
the allocation of funds for basic research. Moreover, those
who are new to research need to learn the value of fundamen-
tal research and its relationship to human disease. The public
who support basic research through their tax dollars and dona-
tions need to understand the relationship between non-direc-
ted, curiosity-driven research and the treatment of human
disease. Thus, ‘‘fundamental research is the basis for under-
standing and treatment of many human diseases’’ is an old
message but one that needs to be repeated often.
Other aspects of basic research are of great importance to
humans that will not be addressed in this article other than
by a brief mention now. Perhaps, of most importance, is the
human quest to understand life on this planet. Societies have
determined that this is an important objective of humanity.
For me, understanding life at the molecular level is a really
important reason for investment in basic research even if there
were no other beneﬁts. Second, related to this is the clear rela-E-mail address: dennis.vance@ualberta.ca (D.E. Vance).
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economic beneﬁt of research needs to be underscored. Clearly,
companies, societies and countries that invest in basic research
eventually reap a ﬁnancial beneﬁt. The discoveries of today
provide the basis for economic beneﬁt to those who invest.
The research process itself stimulates the economy by provid-
ing jobs for individuals who pay taxes. Development of new
treatments for disease means that individuals can continue to
work and be a productive part of the economy. For example,
as we shall see in Section 3 of this article, people are now tak-
ing statins to lower plasma cholesterol and decrease the inci-
dence of heart disease and stroke. So instead of dying or
being conﬁned to a hospital or at home, the patients are work-
ing and paying taxes. Of course, the companies that make the
statins are also an important part of the economy since they
hire individuals to develop, produce and market these drugs.
This article articulates how fundamental research has di-
rectly beneﬁted three diseases. Section 2 is on Fabry disease,
a rare, genetic disorder. Section 3 focuses on cholesterol and
its role in cardiovascular disease. Section 4 describes how fun-
damental research evolved in my own lab into research that
provides new insight into liver disease and provides new ideas
for treatment. Section 5 introduces the theme of this special
issue on lipidomics and disease.2. Fabry disease
Fabry disease was ﬁrst reported in 1898 [1]. It is a rare
X-linked disease. Thus, males carrying the mutation have the
disease whereas females are unaﬀected but are carriers of the
disease. It is characterized by episodes of acute pain, rash
and lipid deposits in various organs, particularly in the kidney.
Death usually occurs during the 4th decade of life. This is a
very succinct summary of what was known when Charles
Sweeley became interested in this disease in the early 1960s.
Dr. Sweeley was trained as a biochemist in the lab of Herbert
Carter at the University of Illinois and had done postdoctoral
training at the National Institutes of Health in the United
States. He joined the faculty at the University of Pittsburgh
in the late 1950s. His training had been oriented towards chem-
istry of sphingolipids and analytical chemistry. There was rea-
son to think that the accumulating lipid in Fabry disease might
be a glycosphingolipid, thus Dr. Sweeley was poised to inves-
tigate the lipid and its structure. During the same time period,
Dr. Sweeley and two other faculty members at the Universityblished by Elsevier B.V. All rights reserved.
D.E. Vance / FEBS Letters 580 (2006) 5430–5435 5431of Pittsburgh, William Wells and Ronald Bentley, had collab-
orated to develop a new method for analysis of carbohydrates
by gas chromatography [2]. This new technique greatly simpli-
ﬁed the identiﬁcation and quantiﬁcation of carbohydrates.
Thus, Charles Sweeley was well prepared to study the structure
of the Fabry lipid. He and his collaborator, Bernard Klionsky,
were soon able to show that the accumulating lipid in Fabry
disease was galactosyl-a-galactosyl-b-glucosyl ceramide [3]
(Fig. 1). Charles Sweeley could not have investigated this dis-
ease successfully without the fundamental research on carbo-
hydrates, sphingolipids and fatty acids that had occurred
prior to 1963. When Emil Fisher was working on the structures
of carbohydrates and Herbert Carter on the structures of
sphingolipids, it is highly unlikely that they had heard of Fabry
disease and were not thinking about the suﬀering these people
were enduring on a daily basis. Yet their fundamental research
and the research of others laid the groundwork for elucidation
of the chemical structure of the Fabry lipid.
The next advance followed quickly. Roscoe Brady and co-
workers at the US National Institutes of Health identiﬁed an
enzyme (a-galactosidase A) that degrades the Fabry lipid to
galactosyl-b-glucosyl-ceramide and they discovered that this
enzyme was missing in patients with Fabry disease (Fig. 1)
[4]. Drs. Sweeley, Brady and others were very interested in fur-
ther advancing the understanding of Fabry disease and were
thinking about treatments. However, other fundamental devel-
opments in science required for treatment of Fabry patients
had not occurred and signiﬁcant advances were not possible
at that time. The treatment at that time was pain killers and
kidney transplantation. Kidney transplants were not well-
developed at that time. Moreover, the patients also had heart
disease, thus their prognosis was not encouraging.
The next signiﬁcant developments did not come until the
1980s. The molecular biology revolution was in progress and
laid the basis for the cloning and expression of the cDNA
encoding the a-galactosidase A and for characterization of
the gene encoding this enzyme [5,6]. In 1997, the generation
of a mouse that lacked the Fabry enzyme provided a new
model system in which to study the disease [7]. The develop-
ment of this gene-disrupted mouse was possible only after a
very signiﬁcant investment of research in the technology of
gene targeting in mice.Fabry Disease
Galα1-4Galβ1-4Glcβ1-1Cer
Galβ1-4Glcβ1-1Cer +   Gal
α-galactosidase A
• Discovered in 1898
• Rare inherited X-linked disease - carried by females, males affected
• Characterized by accumulation of glycosphingolipid Cer-Glc-Gal-Gal
• Heterozygous females have 50% enzyme activity, some symptoms
• Symptoms: rash, accumulation of lipid in kidney, eyes, arteries
• Usually death in 4th decade from kidney failure
Fig. 1. The enzymatic defect in Fabry disease. Fabry disease is caused
by the lack of an enzyme, a-galactosidase A, that normally catabolizes
galactosyl(Gal)a1-4-galactosylb1-4-glucosyl(Glc)b1-1-ceramide to gal
actosylb1-4-glucosylb1-1-ceramide and galactose.Shortly after the discovery of the enzymatic defect, some ef-
forts were made to treat Fabry disease with enzyme replace-
ment therapy [1]. This was an attractive approach since
unlike some other glycosphingolipid storage diseases, Fabry
disease did not aﬀect the brain. Thus, the administered enzyme
did not need to breach the blood–brain barrier. Multiple
experiments demonstrated the feasibility of using enzyme
replacement therapy [1,8]. The major impediment, however,
was to obtain suﬃcient recombinant enzyme for extended
treatment. Developments in molecular biology and enzyme
puriﬁcation allowed two companies to market and test prepa-
rations of a-galactosidase A for treatment of Fabry disease
that are now on the market and are available for long term
use [9]. When the enzyme is injected into the blood, it is inter-
nalized into the cellular lysosomes via the mannose-6-phos-
phate receptor [8].
Another novel approach, which might ultimately reach the
clinic, is to transduce bone marrow mononuclear cells with a
retrovirus that encodes the enzyme, and then introduce the cells
back into a Fabry patient. This approach has been tested suc-
cessfully in a Fabry mouse [10]. Overexpression of a-galactosi-
dase A by transduced cells results in secretion of the enzyme. A
completely diﬀerent idea is to inhibit the biosynthesis of gluco-
sylceramide, a biosynthetic precursor of the Fabry lipid. Stud-
ies in the Fabry mice with this inhibitor indicated its possible
eﬃcacy in humans with the disease [11].
In the example of Fabry disease, we have witnessed in a little
over four decades an understanding of the cause of this disease
and have seen the development of enzyme replacement therapy
that is now available as an eﬀective treatment for the disease. It
is clear that each step for understanding and treatment of this
disease was based on fundamental research by scientists who
initially had no particular knowledge or interest in Fabry
disease.3. Cardiovascular disease – the cholesterol connection
When we talk about our research to our friends and to the
public, there is minimal understanding of what we do and
why. This points to a failure of the education system world-
wide to educate people in science. Despite this shocking rift
in our culture between scientists and non-scientists, when we
tell friends our research is relevant to cholesterol, there is al-
most always a response that indicates that they know about
this molecule. They know that high levels of cholesterol in
the blood stream are associated with an increased incidence
of heart disease and stroke. If the person you were talking to
is middle-aged or older, there would be a very good possibility
that they are taking a medication to lower their serum choles-
terol levels. The cholesterol story is one of the great medical
successes in the past century that occurred as a result of a log-
ical progression of fundamental research that led to successful
therapy.
The start of cholesterol research goes back to the 19th cen-
tury when in 1815 the French chemist, Michel Euge´ne Chev-
reul (Fig. 2), discovered that cholesterol was a component of
human gallstones [12]. There was a long period after that until,
in 1888, Friedrich Reinitzer deduced the chemical formula for
cholesterol (C27H46O). Heinrich Wieland performed most of
the pioneering work on the structure of cholesterol during
the ﬁrst quarter of the 20th century [12]. When the structure
Fig. 2. Photograph of Michel Euge´ne Chevreul, the French scientist
who, in 1815, discovered cholesterol as a component of human
gallstones.
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assembled a 4-ringed, hydrophobic molecule of 27 carbons.
These biosynthetic studies were possible only after physicists
and chemists had devised ways of making stable isotopes to
be used as tracers in experiments. The scientists who provided
this fundamental knowledge would not have anticipated any
connection with heart disease and stroke since the cholesterol
connection was not known at that time. Thus, Rudi Schoen-
heimer at Columbia University pioneered the use of these trac-
ers to determine how various molecules were assembled in cells
and tissues [12]. In 1941, Dr. Schoenheimer had an untimely
death and one of his postdoctoral fellows, Konrad Bloch, be-
came the leading scientist who would determine how choles-
terol was biosynthesized. Dr. Bloch was also not thinking
about cardiovascular disease but rather was curious how this
complex molecule was assembled. Research in the 1940s,
1950s and 1960s from Bloch’s lab and many other labs eluci-
dated the exquisite pathway for cholesterol biosynthesis [12].
One of the key enzymes in this pathway, b-hydroxy-b-methyl-
glutaryl-CoA reductase (HMG-CoA reductase) was described
in the late 1950s by the groups of Harry Rudney and Fydor
Lynen [13].
With the biosynthesis of cholesterol becoming well under-
stood, scientists began studies on the regulation of cholesterol
biosynthesis. Drs. Schoenheimer and Breusch reported in 1933
that cholesterol biosynthesis in mice was subject to feedback
regulation by dietary cholesterol [14]. This observation was
studied further by Gordon Gould in the 1950s and the results
conﬁrmed that feedback inhibition of cholesterol biosynthesis
occurred in dog liver [15,16]. Since that time many labs have
made substantive contributions to our understanding of the
regulation of cholesterol biosynthesis. However, the contribu-
tions from Michael Brown and Joseph Goldstein’s lab are leg-
endary. Interestingly, a recent paper from their lab [17]
describes in detail the molecular mechanism for feedback reg-
ulation of cholesterol biosynthesis originally described bySchoenheimer. In contrast to most of the scientists mentioned
so far, Drs. Brown and Goldstein did have treatment of dis-
eases of cholesterol metabolism in mind when they began their
fundamental research. They postulated that in order to treat
diseases of cholesterol metabolism, they needed to understand
regulatory mechanisms [18]. As we shall see below, the cur-
rently very successful treatment of elevated plasma cholesterol
with statin drugs did not depend directly on the research of
Drs. Brown and Goldstein. However, the elegant work of this
lab explains the mechanisms by which statins operate.
I have stated that the early scientists investigating cholesterol
structure and metabolism were unaware of the association be-
tween elevated plasma cholesterol and cardiovascular disease.
However, this is not strictly true. Daniel Steinberg in a series
of reviews has argued cogently that the association between
cholesterol and atherosclerosis has been known for 100 years
and that suﬃcient evidence existed in the 1960s to merit major
eﬀorts to lower plasma cholesterol in humans [19–23]. The the-
sis of these excellent reviews is that physicians should have rec-
ognized this much earlier and acted on it. Only in 1984 did a
large clinical study demonstrate that lowering of plasma cho-
lesterol in hypercholesterolemic men results in a 19% decrease
in coronary events [22].
It is nowwell-recognized that a daily oral dose of a statin is an
eﬀective treatment for lowering plasma cholesterol and decreas-
ing mortality from cardiovascular disease [23]. Statins were not
discovered as a result of curiosity-driven research.Rather,Akira
Endo began experiments to search for an inhibitor of cholesterol
biosynthesis in the media in which fungi were grown [24]. Dili-
gent screening ﬁnally yielded a potent inhibitor of cholesterol
biosynthesis, compactin, that inhibited the activity of HMG-
CoA reductase [25]. Endo subsequentlywas contacted byBrown
and Goldstein and they collaborated on studies showing that
compactin induced the expression of the reductase [26]. Since
that time several pharmaceutical companies have developed re-
lated statins that have proved eﬀective in treatment of cardiovas-
cular disease induced by hypercholesterolemia.
In this second example we see clearly that fundamental re-
search on the structure and biosynthesis of cholesterol as well
as the development of radioactive tracer methodologies pro-
vided the necessary information for development of an eﬀec-
tive therapy for cholesterol-induced cardiovascular disease.4. Unexpected relationships between phosphatidylcholine
biosynthesis and disease
4.1. The Kennedy (choline) pathway
Phosphatidylcholine (PC) was discovered as an important
component of egg yolk in 1847 by Gobley. In the 1860s Diako-
now and Strecker determined that PC was composed of two
fatty acids, glycerol, phosphate and choline. For scientists in
2006 it is hard to imagine how scientists in the 1860s could
have known so much about PC with the crude methods and
equipment available to them at that time. With knowledge of
the structure of PC, the stage was set for studies on PC biosyn-
thesis but it was only in 1932 that Charles Best discovered
that animals had a dietary requirement for choline [27]. Two
more decades were to pass before the DNA biochemist and
enzymologist, Arthur Kornberg, discovered choline kinase
[28]. Shortly thereafter, Eugene Kennedy and co-workers
described the pathway by which animal cells make PC from
Choline
Pathway
CDP-choline
Phosphocholine
Choline
PC
PEMT
Pathway
PE 
PMME 
PDME 
(30%) (70%)
Membranes
Signaling
Bile
Lipoproteins
CT
Fig. 3. The major biosynthetic pathways by which phosphatidylcho-
line (PC) is made in liver. PC is a major component of hepatic
membranes, is a precursor of signaling molecules, is an important
component of bile and is required for very low density lipoprotein
secretion. CT, CTP:phosphocholine cytidylyltransferase; PEMT, phos-
phatidylethanolamine N-methyltransferase; PE, phosphatidylethanol-
amine; PMME, phosphatidylmonomethylethanolamine; PDME,
phosphatidyldimethylethanolamine.
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that was involved in the biosynthesis of PC provides instruc-
tive reading about the importance of using pure reagents [30].
After the 1950s there were two decades of relatively minor
advances in understanding PC biosynthesis. A major reason
was that two of the three enzymes in the choline pathway were
membrane associated and refractory to puriﬁcation. The trials
and tribulations associated with puriﬁcation of membrane-
bound proteins has been termed ‘‘masochistic enzymology’’
[31]. In the 1970s it was discovered that CTP:phosphocholine
cytidylyltransferase (CT) catalyzed the rate-limiting step in
PC biosynthesis [32,33]. This was probably not anticipated
since choline kinase catalyzes the ﬁrst and committed step in
PC biosynthesis yet the next enzymatic reaction catalyzed by
CT is normally the regulated and rate-limiting enzyme. Next
Claudia Kent showed that CT is regulated by translocation
from a soluble inactive form to an active membrane-bound
form [34]. This ﬁnding was conﬁrmed in many diﬀerent cell
types [35]. Mechanisms have since been discovered to show
how this translocation is governed [36–39]. Another unex-
pected ﬁnding was that in many cells, the ‘‘soluble’’ form of
CT is primarily in the nucleus [40]. Why CT should be located
in the nucleus while the other two enzymes in the pathway are
cytoplasmic remains an enigma.
When Roger Sher and Greg Cox were trying to identify the
gene responsible for hind limb muscular dystrophy in a mouse,
they certainly did not think that the basic research of Arthur
Kornberg, Eugene Kennedy and many others would impact
on their studies. Yet, they found that the inherited gene defec-
tive in these mice is in an isoform of choline kinase, choline ki-
nase b [41]. Why this genetic deletion leads to muscular
dystrophy is currently under investigation.
4.2. The phospholipid methylation pathway
In 1960/61 Jon Bremer and David Greenberg described an-
other pathway for the biosynthesis of PC by the conversionof phosphatidylethanolamine to PC in which S-adenosylmethi-
onine was the methyl donor [42] (Fig. 3). The enzyme catalyzing
this reaction, phosphatidylethanolamine N-methyltransferase
(PEMT), was found to be located on microsomes and mainly
recovered from the livers of rats but with much less activity
in other tissues. Despite the challenges of ‘‘masochistic enzy-
mology’’ PEMT was successfully puriﬁed to homogeneity in
1987 [43]. Determination of the partial sequence of PEMT
and developments in molecular biology permitted the cloning
and expression of the cDNA encoding PEMT [44]. The next
signiﬁcant advance was to obtain mice with a targeted deletion
in the gene encoding PEMT [45]. These Pemt/mice lived and
bred normally with no obvious phenotype. This was not a sur-
prise since the Pemt/mice still made PC via the CDP-choline
pathway that was upregulated. However, when we did the
Charles Best experiment and fed the mice a choline-deﬁcient
diet, liver failure occurred after 3–4 days [46]. The main scien-
tiﬁc conclusion of these studies was that PEMT has survived in
evolution to provide PC (and choline) when dietary choline is
inadequate as would occur during starvation.
When Jon Bremer began his experiments on PEMT, it is un-
likely that he was thinking about liver failure. After several
decades of studies on PEMT, I did not anticipate that my fun-
damental research would provide insight into the mechanism
for liver failure. Yet, in 1998, we discovered a new model of
liver failure when we fed the Pemt/ mice a diet deﬁcient in
choline. Our curiosity directed us to investigate the mechanism
by which these mice developed liver failure yet the other tissues
in the mice appeared normal. The Pemt/ mice exhibit a 50%
decrease in PC in the liver when fed a choline deﬁcient diet [46].
Since the mouse secretes the equivalent of its entire pool of PC
in the liver into bile during a 24 h period, we postulated that
this could explain the rapid decline in PC that led to apoptosis
[46]. Earlier studies by Christian Raetz and co-workers demon-
strated that cells require PC to survive [47]. This was conﬁrmed
by additional studies that showed that Chinese hamster ovary
cells die via apoptosis when PC biosynthesis is completely cur-
tailed [48]. With the availability of Pemt/ mice we were able
to test the hypothesis that rapid liver failure occurred due to
secretion of PC into bile. We bred the Pemt/ mice with mice
that lacked the ﬂippase (Mdr2, Abcb4) responsible for export
of PC into bile. The results showed that instead of dying after 3
days the double knockout Pemt/Mdr2/ mice lived for
more than 90 days [49]. Although it was satisfying to see that
Pemt/ mice survived when they no longer secreted PC into
bile, we were very surprised to ﬁnd that the amount of PC also
decreased by 50% in the livers of the Pemt/Mdr2/ mice.
Thus, a decrease in PC per se did not cause the liver failure.
Further studies established that liver failure resulted not from
a decrease in PC itself, but rather from a decrease in the
amount of PC relative to phosphatidylethanolamine [50]. This
decrease in the PC/phosphatidylethanolamine ratio promotes
leakage from hepatocytes and subsequently causes cell death.
Fatty liver (steatosis) can progress to steatohepatitis which
often leads to liver failure [51]. The Pemt/ mice fed a choline
deﬁcient diet are, thus, a model for liver failure. Non-alcoholic
fatty liver disease (NAFLD) aﬀects between 14% and 24% of
populations and is increasing, most likely due to the steady rise
in obesity in adults and children in Western countries. Thus,
the research on Pemt/ mice has yielded a novel model for
the transition of steatosis to steatohepatitis. Moreover, in a
preliminary study of hepatic biopsies from patients with
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crease in the ratio of PC to phosphatidylethanolamine [50].
Thus, the curiosity-driven research on PEMT beginning with
seminal work of Drs. Bremer and Greenberg has led to novel
insights into liver disease in humans and suggests possible
strategies for treatment.5. Lipidomics and disease
In the three examples of lipid research leading to under-
standing human diseases, fundamental-curiosity driven re-
search was required before the advancements on
understanding these diseases could be made. Clearly this is
not limited to these diseases, but applies to our understanding
and treatment of virtually all human diseases. This special is-
sue of FEBS Letters provides an update on research on many
other disorders that involve abnormalities in lipid metabolism.
A theme that runs through these articles is that all of the
advancements are based on fundamental research. Mostly,
the diseases discussed are not well understood and treatments
are less than optimal. Nevertheless, while it is certainly impor-
tant to investigate these diseases directly, it is very likely that
research completely unrelated to these disorders will provide
crucial information that will impact directly on understanding,
diagnosis and treatment.
The technology to measure molecular species of all lipids is
now emerging and within the next decade we can anticipate
that we shall be able to quantify by mass spectrometry all
of the molecular species of a lipid class in a cell or puriﬁed
membranes. Thus, in the future we should be able to measure
not only the ratio of PC to PE in liver samples but the amount
of the various molecular species of PC and PE. We may ﬁnd
that there are also signiﬁcant changes in these parameters in
the transition from steatosis to steatohepatitis. Such addi-
tional information should provide more insight into liver
disease.
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